<DOC>
	<DOCNO>NCT01777256</DOCNO>
	<brief_summary>This adaptive , dose ranging , Phase II study investigate relationship repeat dose GSK2586184 pharmacodynamic effect clinical efficacy patient active systemic lupus erythematosus ( SLE ) . This study also investigate safety tolerability repeat dose GSK2586184 . During study , 3 Interim Analyses conduct . These monitor pharmacodynamic effect safety follow 2 week therapy ( Interim Analysis 1 ) ; clinical efficacy safety GSK2586184 follow 12 week therapy ( Interim Analyses 2 3 ) . Subjects meet entry criterion ( approximately 150 250 ) randomize 1:1:1:1:1 ratio receive GSK2586184 dose 50 milligram ( mg ) twice daily ( b.i.d ) , 100 mg b.i.d , 200 mg b.i.d , 400 mg b.i.d Placebo b.i.d . GSK2586184 tablets available 50 200 mg dose strength administer orally 12 week . Subjects complete study participate study approximately 21 week .</brief_summary>
	<brief_title>An Adaptive Phase II Study Evaluate Efficacy , Pharmacodynamics , Safety Tolerability GSK2586184</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<criteria>Age &amp; Gender : Male female 18 75 year age inclusive SLE classification : clinical diagnosis SLE accord American College Rheumatology ( ACR ) classification criterion Severity disease : clinically active SLE disease define SELENA SLEDAI score â‰¥8 screen Auto antibody : serologically active unequivocally positive antinuclear antibody ( ANA ) antidouble strand DNA ( antidsDNA ) antibody test result 2 independent time point Treatment SLE : patient stable either treatment stable dose : corticosteroid ( &lt; =15 mg/day prednisolone equivalent ) /or hydroxychloroquine ( &lt; =400 mg daily dose ) Subjects receive azathioprine ( &lt; =2 mg/kg/day &lt; =150 mg/day , whichever great ) mycophenolate mofetil ( &lt; =1.5 g/day ) , methotrexate ( MTX ) ( &lt; =20 mg/week ) , either alone addition steroid / hydroxychloroquine Prevention Pregnancy : A female Subject eligible participate pregnant nursing ; nonchildbearing potential . Females childbearing potential must agree use one highly effective contraception method addition barrier protection OR two form highly effective contraception . Informed consent : Capable give write informed consent Kidney Disease : meeting follow criterion : Proteinuria &gt; 0.5g/24 hour OR equivalent spot urine protein creatinine ratio 0.5mg/mg ; Serum creatinine &gt; 1.5 X upper limit normal ( ULN ) ; active nephritis require acute therapy permit protocol ; require peritoneal dialysis hemodialysis high dose corticosteroid ( &gt; 100 mg/day prednisone equivalent ) within 90 day prior first dose ; active renal disease show renal biopsy three month prior screen . CNS Disease : active central nervous system ( CNS ) lupus ( include seizure , psychosis , organic brain syndrome , cerebrovascular accident [ CVA ] , cerebritis CNS vasculitis ) require therapeutic intervention within 60 day prior first dose . Alcohol Abuse : Evidence , opinion investigator , suspicion alcohol consumption exceed national guideline / symptom alcohol dependency . Substance abuse : evidence current recreational drug abuse dependence . Hepatitis B : A positive prestudy Hepatitis B surface antigen antiHepatitis B core antibody test screen Hepatitis C : A positive Hepatitis C antibody screen . HIV : A positive test HIV antibody Previous Investigational Product Exposure : The subject participate clinical trial receive investigational product within 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) prior first dose day current study ; OR exposure four new chemical entity within 12 month prior first dose day . Previous current medication : Use prescription nonprescription drug , include : agent know interact GSK2586184 , erythopoetic stimulation factor ; vitamin , herbal dietary supplement Prior biological therapy : treatment biological therapy within last 12 month Transplantation : Have history major organ transplant ( e.g. , heart , lung , kidney , liver ) hematopoietic stem cell/marrow transplant . Uncontrolled Other Diseases : Have clinical evidence significant unstable uncontrolled acute chronic disease due SLE , opinion investigator , could confound result study put subject undue risk . Surgery Other Conditions : Have plan surgical procedure history medical disease laboratory abnormality , condition , opinion investigator , make subject unsuitable study . Cancer : Have history malignant neoplasm within last 5 year , except adequately treat cancer skin ( basal squamous cell ) carcinoma situ uterine cervix . Infections : require management acute chronic infection follow : currently suppressive therapy chronic infection ( pneumocystis , cytomegalovirus , herpes simplex virus , herpes zoster atypical mycobacteria ) ; OR hospitalisation treatment infection OR use parenteral ( IV intramuscular ) antibiotic ( antibacterial , antiviral , antifungal , anti parasitic agent ) within 60 day prior first dose . Mycobacterium Tuberculosis : Known latent active infection Mycobacterium Tuberculosis . Screening procedure consistent local guideline implement . Haematology : neutrophil count &lt; =1.5 X 10^9/L , Hb &lt; =10g/dL , lymphocyte count &lt; =350/mm^3 0.35 x 10^9/L platelet count &lt; =100 X 10^9/L Serum immunoglobulin ( Ig ) level : IgG and/or IgM &lt; = low limit normal ( LLN ) Liver function test : Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; =2x upper limit normal ( ULN ) ; alkaline phosphatase bilirubin &gt; 1.5xULN ( isolated bilirubin &gt; 1.5ULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Other laboratory abnormality : Any Grade 3 4 haematology clinical chemistry laboratory abnormality Drug sensitivity : History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . Blood donation : Where participation study would result donation blood blood product excess 500 mL within 56 day period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>systemic lupus erythematosus</keyword>
	<keyword>adaptive design</keyword>
	<keyword>clinical safety efficacy</keyword>
	<keyword>pharmacodynamics</keyword>
</DOC>